Results 221 to 230 of about 71,313 (303)
Retraction: Machine Learning-Based Prediction of COVID-19 Prognosis Using Clinical and Hematologic Data. [PDF]
Kamel FO +16 more
europepmc +1 more source
Objective Rituximab, a CD20+ B cell depletion therapy, is frequently used to treat systemic lupus erythematosus (SLE). However, variability in patient response highlights the need for a deeper understanding of the underlying immune cell dynamics of B cell depletion and repopulation.
Haerin Jang +9 more
wiley +1 more source
Polygenic risk scores and LDL cholesterol: Improving precision in primary cardiovascular prevention. [PDF]
Rana JS, Shabani M.
europepmc +1 more source
Objective Immune checkpoint inhibitors (ICIs) for cancer can lead to immune‐related adverse events, including ICI‐associated inflammatory arthritis (ICI‐IA). There are no validated International Classification of Diseases (ICD) code–based case definitions for ICI‐IA.
Manar Elsayed +11 more
wiley +1 more source
The Impact of Endoscopic Dilatation in Post-Esophagectomy Anastomotic Stricture: Risk Factors and Treatment Outcomes. [PDF]
Jamal M +6 more
europepmc +1 more source
Background CD4 T cells specific for citrullinated (cit)‐peptides are key players in RA immunopathogenesis. Characterising these cells and identifying features of healthy and RA‐associated autoreactivity will provide valuable insight into disease mechanisms and form the basis of immune state biomarkers to facilitate the next generation of RA treatments.
James A. Stanway +13 more
wiley +1 more source
Low-Dose Systemic Thrombolysis as Rescue Therapy After Catheter-Directed Thrombectomy for High-Risk Pulmonary Embolism on VA-ECMO. [PDF]
Nehete S +4 more
europepmc +1 more source
Objective Anti‐homocitrullinated protein/peptide antibodies are specific to rheumatoid arthritis (RA) and predictive of worse prognosis, suggesting a pathogenic role for autoreactivity to homocitrullinated peptides (HomoCitP). However, T cell responses to HomoCitP remain largely unexplored.
Sofya Ulanova +6 more
wiley +1 more source

